Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

TMTA - Transmeta Corporation - Deel 2

226 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 12 »» | Laatste | Omlaag ↓
  2. positivo73 12 maart 2007 13:43

    • positivo73

      Lid sinds: 25 mrt 2004

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 370

      Gegeven: 163

    •    Aantal posts: 6.036

    quote:

    welshterrier schreef:

    opgave van 15 febr staan er wel heel veel short ruim 12 milj, die zullen toch een keer moeten coveren.
    Daarom staan we nu ook zo laag. Ze hebben wel weer veel verdiend met deze actie. Binnen enkele weken staan we m.i. weer boven de $1.
  6. positivo73 13 maart 2007 20:16

    • positivo73

      Lid sinds: 25 mrt 2004

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 370

      Gegeven: 163

    •    Aantal posts: 6.036

    quote:

    sethonno schreef:

    er wordt heel veel gekocht op 0.68
    Sinds ik vorige week woensdag een pluk gekocht heb, is de koers bijna niet van zijn plaats geweest. dagelijks gaan er erg veel op 0,68 en 0,69. Zou het acumuleren zijn? Zo ja, dan kunnen we op zeer korte termijn al een flinke stijging verwachten.
  13. [verwijderd] 28 maart 2007 21:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    TMTA: Receives Nasdaq Delisting Notice

    By Jay Everitt, jeveritt@knobias.com

    Transmeta Corporation (TMTA) announced that on March 21, 2007 it received a letter from the Nasdaq Stock Market indicating that Transmeta is not in compliance with the Nasdaq Stock Market's requirements for continued listing because, for the previous 30 consecutive business days, the bid price of Transmeta's common stock had closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule"). Nasdaq stated in its letter that in accordance with the Nasdaq Marketplace Rules, Transmeta will be provided 180 calendar days, or until September 17, 2007, to regain compliance with the Minimum Bid Price Rule. This notification has no effect on the listing of the Company's common stock at this time.

    The Nasdaq letter also states that if, at any time before September 17, 2007, the bid price of Transmeta's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Nasdaq staff will provide the Company written notification that it has achieved compliance with the Minimum Bid Price Rule. However, the letter states that if the Company does not regain compliance with the Minimum Bid Price Rule by September 17, 2007, the Nasdaq staff will provide the Company with written notification that its common stock will be delisted from the Nasdaq Stock Market.

    In the event that Transmeta were to receive notice that its common stock is delisted from the Nasdaq Stock Market, Nasdaq rules permit Transmeta to appeal any delisting determination by the Nasdaq staff to a Nasdaq Listings Qualifications Panel. In addition, in the event that such a delisting determination was based solely on non-compliance with the Minimum Bid Price Rule, Nasdaq Marketplace Rule 4450(i) may permit the Company to transfer its common stock to the Nasdaq's Capital Market if the Company's common stock satisfies all criteria for initial inclusion on such market other than compliance with the Minimum Bid Price Rule. In the event of such a transfer, the Nasdaq Marketplace Rules provide that the Company would be provided an additional 180 calendar days to comply with the Minimum Bid Price Rule while on the Nasdaq Capital Market.
  15. welshterrier 5 2 april 2007 17:27

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1100

    •    Aantal posts: 20.113

    [quote=sethonno]
    wat is er hier aan de hand
    [/quTMTA
    Transmeta Corporation NASDAQ-GM




    Back to Headlines | Previous Story | Next Story



    Transmeta Files 2006 Annual Report With SEC and Provides Progress Update on 2007 Restructuring Plan

    Company Announces Going Concern Qualification in Accordance With Nasdaq Marketplace Rule 4350(b)(1)(B)

    SANTA CLARA, Calif.--(BUSINESS WIRE)--

    Transmeta Corporation (NASDAQ:TMTA) today announced that it took additional steps during March 2007 to streamline its operations under its restructuring plan, and that it filed its 2006 annual report on Form 10-K with the Securities and Exchange Commission on March 30, 2007.

    Transmeta's annual report includes an audit report by the Company's independent registered public accounting firm containing a going concern qualification. The Company makes this announcement in compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires any Nasdaq listed issuer that receives an audit opinion that contains a going concern qualification to make a public announcement to that effect through the news media. This announcement and press release do not represent any amendment to Transmeta's 2006 Annual Report on Form 10-K.

    Transmeta's 2006 annual report describes the company's plans to address its liquidity and capital resources needs, including the company's restructuring plan announced in February 2007 to realign its headcount and expenses with its core business of developing and licensing its technology and intellectual property. During the initial phase of this plan, implemented on February 2, 2007, the Company decreased its worldwide workforce by approximately 75 employees, most of whom worked in the Company's engineering services business.

    In March 2007, Transmeta took the next steps in its restructuring plan and reduced its headcount by an additional 55 workers effective March 31, 2007. The March reduction primarily affected employees who had remained with the Company to complete engineering services work for Sony and Microsoft, as well as employees who supported the Company's microprocessor production support operations.

    As of March 31, 2007, the Company's restructuring plan had also effectively eliminated the management positions of at least four of the Company's executive officers: Patrick V. Boudreau, senior vice president of human resources; David R. Ditzel, chief technology officer; Martin A. Levy, vice president of operations; and Robert Rogenmoser, vice president of VLSI development.

    At March 31, 2007, the Company had approximately 65 employees.
    The Company reiterates its earlier estimate that the February and March workforce reductions will result in cumulative restructuring charges in the range of $11 million to $14 million, the vast majority of which will be an expense in the first quarter of 2007. The Company estimates these actions will require total cash expenditures of $7 million to $10 million, which will be incurred primarily in the first quarter. The Company expects these actions to generate cost savings in the range of $17 million to $23 million on an annualized basis.

    As a result of its recent operational streamlining activities, Transmeta has ceased to pursue engineering services as a separate line of business, has ceased its operations relating to microprocessor production support, and has exited the business of selling microprocessor products. As announced in February 2007, the Company will focus on its primary line of business in developing and licensing its advanced technologies and intellectual property.

    "Over the past two months, we have taken difficult but important steps to realign our headcount and expenses with our core business of developing and licensing technology and intellectual property," said Les Crudele, Transmeta's president and chief executive officer. "To further streamline our operations under our current business model, we expect to reduce our headcount by 15 to 20 percent during the second quarter of 2007. We believe these actions will result in a better financial position from which Transmeta can execute on its new business model."

    About Transmeta Corporation

    Transmeta Corporation develops and licenses innovative computing, microprocessor and semiconductor technologies and related intellectual property. Founded in 1995, we first became known for designing, developing and selling our highly efficient x86-compatible software-based microprocessors, which deliver a balance of low power consumption, high performance, low cost and small size suited for diverse computing platforms. We are presently focused on developing and licensing our advanced power management technologies for controlling leakage and increasing power efficiency in semiconductor and computing devices, and in licensing our computing and microprocessor technologies to other companies. To learn more about Transmeta, visit www.transmeta.com.

    Safe Harbor Statement

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements speak only as of the date of this release, and we will not necessarily provide updates of our projections or other forward-looking statements. Investors are cautioned that such forward-looking statements are subject to many risks and uncertainties, and may differ materially or adversely from our actual results or future events. Important risk factors that could have material or adverse effects on our results include practical difficulties in implementing our restructuring plan and modifying our business model, the potential loss of key technical and business personnel, our ability to satisfy the continued listing requirements of the Nasdaq Stock Market, uncertainty about the adoption and market acceptance of our technology offerings by current and potential customers and licensees, our inability to predict or ensure that third parties will license our technologies or use our technologies to generate royalties, difficulties in developing our technologies in a timely and cost effective manner, the risk that we have difficulties entering into strategic collaborations or raising financing on satisfactory terms, patents and other intellectual property rights, and other risk factors. We urge investors to review our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K and 8-K, which describe these and other important risk factors that could have an adverse effect on our results. We undertake no obligation to revise or update publicly any forward-looking statement for any reason.

    Source: Transmeta Corporation

    ote]
  17. welshterrier 5 3 april 2007 19:01

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1100

    •    Aantal posts: 20.113

    er ligt een grote bied op 0,50 en een grote laat op 0,52, waarschijnlijk om verkopen uit te lokken op 0,51 denk iki meer dan 5 miljoen stuks al.
    er staan geloof ik 14 milj short per 15 maart.
    wie heeft ze nog in porto??
  18. [verwijderd] 3 april 2007 19:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    er ligt een grote bied op 0,50 en een grote laat op 0,52, waarschijnlijk om verkopen uit te lokken op 0,51 denk iki meer dan 5 miljoen stuks al.
    er staan geloof ik 14 milj short per 15 maart.
    wie heeft ze nog in porto??
    Ik,.....helaas....
226 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 12 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.198
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.517
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.651
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.995
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.324
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.717
AMG 971 133.054
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 483
Antonov 22.632 153.605
Aperam 92 14.918
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.571
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.994
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390